Definium Therapeutics to Participate at Upcoming Investor Conferences and Events
Results Call • Phase 3Results call Tue, Sep 1, 2026, 1:00 PM ET
Company profile
Definium Therapeutics, Inc. -
Pipeline2 assets
- DT120 ODTDT120 / serotonin receptors / Orally disintegrating tablet formulation of lysergide (LSD) D-tartrate / Psychiatry / brain healthGeneralized anxiety disorderPhase 3Two Phase 3 registrational trials ongoing/evaluating efficacy and safetyU.S.EuropeMajor depressive disorderPhase 3Emerge Phase 3 ongoing; Ascend Phase 3 expected to initiate mid-2026U.S.
- DT402DT402 / serotonergic system / R-enantiomer of MDMA (R(-)-MDMA) / Neurodevelopmental disordersAutism spectrum disorderPhase 2aPhase 2a study initiated after completion of Phase 1 single-ascending dose study
Latest news25 items
All newsDefinium Therapeutics Announces Positive Topline Results from Phase 3 Voyage Study of DT120 ODT in Generalized Anxiety Disorder
Trial Results • Phase 3Topline results release Wed, Aug 12, 2026, 7:00 AM EDT
Definium Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights
Trial Results • Phase 3Results event Mon, Jun 30, 2025, 4:30 PM EDT
Definium Therapeutics Announces Positive Topline Results from Phase 3 Emerge Study of DT120 Orally Disintegrating Tablet (ODT) in Major Depressive Disorder
Trial Results • Phase 3Topline results Mon, Jun 22, 2026, 7:00 AM EDT
Definium Therapeutics to Discuss Topline Results from Phase 3 Emerge Study in Major Depressive Disorder on June 22, 2026
Results Call • Phase 3Results call Mon, Jun 22, 2026, 8:00 AM EDT
Definium Therapeutics Announces First Patient Dosed in Ascend, the Second Phase 3 Pivotal Study of DT120 ODT in Major Depressive Disorder
Trial Start • Phase 3Trial initiation Tue, May 12, 2026, 7:00 AM EDT